Telomere Length in Breast Cancer Patients Before and After Chemotherapy
Author Information
Author(s): C P Schröder, G B A Wisman, S de Jong, W T A van der Graaf, M H J Ruiters, N H Mulder, L F M H de Leij, A G J van der Zee, E G E de Vries
Primary Institution: University Hospital Groningen, The Netherlands
Hypothesis
High-dose chemotherapy and stem cell transplantation may accelerate telomere length loss in hematopoietic stem cells.
Conclusion
Both standard and high-dose chemotherapy negatively affect blood cell recovery in breast cancer patients.
Supporting Evidence
- Leukocyte telomere length was assessed before and after treatment.
- Patients receiving high-dose chemotherapy showed decreased blood cell counts.
- Telomere length changes ranged from +0.8 to -2.2 kb in individual patients.
Takeaway
This study looked at how chemotherapy affects the length of telomeres, which are the protective ends of our DNA, in breast cancer patients. It found that chemotherapy can shorten these telomeres.
Methodology
The study assessed leukocyte telomere length and telomerase activity before and after treatment in breast cancer patients receiving different chemotherapy regimens.
Participant Demographics
Breast cancer patients receiving chemotherapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website